Visx CustomVue approved for hyperopia
This article was originally published in The Gray Sheet
Executive Summary
Vision correction system is the first wavefront-guided laser cleared by FDA for hyperopia with or without astigmatism, Visx says. The expanded indication increases the percentage of the 50 mil.-60 mil. people eligible for LASIK from 75% to 90%. CustomVue previously was approved for low-to-moderate myopia and astigmatism; studies are underway for expanded myopia treatment (1"The Gray Sheet" Nov. 1, 2004, p. 22)...
You may also be interested in...
Visx Eyes Expanded CustomVue Indications, Readies U.S. Presbyopia Trial
Visx is counting on expanded hyperopia and myopia claims to its CustomVue wavefront ablation system to spur 8%-10% sales growth in 2005
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.